Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Academy Webinar: How to Use Antidotes for the Reversal of DOACs
Tell a Friend About This EventTell a Friend
ISTH Academy Webinar: How to Use Antidotes for the Reversal of DOACs

When: 4/12/2016
18:30 UTC

« Go to Upcoming Event List  

How to Use Antidotes for the Reversal of Direct Oral Anticoagulants

ISTH Core Curriculum 13.1, 13.2, 13.4, 13.5 – Antithrombotic agents

April 12, 2016 18:30 - 19:30 UTC


Peter Verhamme "Idarucizumab"

Mark Crowther "Andexanet"

Moderator: Jerrold Levy

Sign in and register here! 



Peter Verhamme, MD, PhD

Peter Verhamme is a physician at the Department of Cardiovascular Medicine and coordinator of the Vascular Medicine and Haemostasis Unit of the University Hospitals Leuven, Belgium.

His main clinical interests and clinical research programmes concern the prevention and treatment of venous and arterial thrombosis. He was actively involved in many clinical trials: as (principal) investigator, as national coordinator and/or as steering committee member.

He is also principal investigator of research programmes at the Center for Molecular and Vascular Biology, University of Leuven, focussing on new fibrinolytic and antithrombotic strategies, and on the interactions between infection and coagulation.

Professor Verhamme is currently Chair of the Thrombosis Guidelines Group and co-Chair of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

He obtained his MD at the University of Leuven, Belgium in 1997, and completed a PhD on oxidized low-density lipoprotein and atherothrombosis. Professor Verhamme has co-authored more than 130 papers published in peer-reviewed journals.

Mark Crowther

Dr. Mark Crowther received his M.D. from the University of Western Ontario in 1990. Subsequently, he undertook Internal Medicine training at the University of Western Ontario, followed by Hematology training at McMaster University in Hamilton, Ontario Canada.

Between 1995 and 1999, Dr. Crowther undertook a focused Research Fellowship in Thromboembolism under the direction of Drs. Ginsberg, Weitz and Hirsh. Dr. Crowther joined the faculty at McMaster University in 1999 as an Assistant Professor in the Department of Medicine working at St. Joseph's Hospital.

Currently, Dr. Crowther is Chair of the Department of Pathology and Professor in the Departments of Pathology and Molecular Medicine, Medicine and Clinical Epidemiology and Biostatistics. He is also the Vice President of Research at St. Joseph's Healthcare in Hamilton and sits on the Board of Directors of the St Joseph’s International Research Program.

Dr. Crowther's clinical activities focus on the care of patients with thromboembolic disorders, the management of complications of treatments for thromboembolic disorders and other hematologic conditions. Dr. Crowther's research endeavors include a wide variety of projects examining the optimal methods to prevent and treat both arterial and venous thrombosis.

Dr. Crowther has presented more than 400 invited talks, published more than 350 peer-reviewed publications, spoken nationally and internationally and is the author of chapters in many bleeding hematologic texts. He is a Career Investigator award from the Heart and Stroke Foundation of Ontario.

Jerrold H Levy, MD, FAHA, FCCM

Duke University Medical Center, Durham, NC, USA


Jerrold Levy is Professor of Anesthesiology, Associate Professor of Surgery, and Co-Director of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center, Durham, NC, USA. He obtained his medical degree from the University of Miami, FL, where he was an intern in medicine, and undertook his residency in the Department of Anesthesiology of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, where he also completed two fellowships in Cardiac Anesthesia and in the Respiratory Intensive Care Unit.


Dr Levy’s main clinical and research interests include: therapeutic strategies to prevent and treat bleeding; anticoagulation and its reversal; thrombin generation; clinical applications of recombinant and purified protein concentrates; therapeutic approaches to shock; and anaphylactic reactions/mast cell activation. He holds numerous regional and national committee positions, including consultant to the Food and Drug Administration‘s Blood Products Advisory Committee; fellow and member of the American Heart Association Leadership Committee‘s Council on Cardiovascular Surgery; fellow of the American Board of Critical Care Medicine; and on the Board of Directors for the Foundation for the Advancement of Cardiothoracic Surgical Care. He is an executive editor ofAnesthesiology, and was previously a section editor for Hemostasis and Transfusion Medicine. He has authored over 400 publications, including original research articles, reviews, books, and book chapters.


Sponsored by an unrestricted
educational grant from:

Membership Management Software Powered by YourMembership  ::  Legal